Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicines Shortage Risk Builds In Ireland

There Are Currently 180 Medicines In Short Supply In Ireland

Executive Summary

Medicines for Ireland has called for action on risks to the country’s medicines supply, with 180 products currently listed as being in shortage.

You may also be interested in...



Irish Industry Pact Offers Stability And Visibility

A four-year agreement reached between Medicines for Ireland and the Irish government offers suppliers visibility and stability thanks to a combination of clear pricing mechanisms as well as the promise of uptake drivers, the off-patent industry association says.

Ireland’s Supply Chain Suffers Due To Brexit And Covid

Medicines for Ireland has released a report focusing on the direct impact of Brexit and COVID-19 on the medicines supply chain. The association has called for long-term plans and solutions instead of temporary fixes for issues related to delays in the import and export of medicines. 

Numerous US Approvals Received By Lupin Following 278% Quarterly Profits Raise

Lupin has announced a number of drug approvals in the US, as well as a biosimilar partnership in the Middle East and the launch of a novel fixed-dose triple combination drug in its native Indian market.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152239

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel